CN117377675A - 含有并环或螺环的布鲁顿酪氨酸激酶降解剂 - Google Patents

含有并环或螺环的布鲁顿酪氨酸激酶降解剂 Download PDF

Info

Publication number
CN117377675A
CN117377675A CN202280037318.XA CN202280037318A CN117377675A CN 117377675 A CN117377675 A CN 117377675A CN 202280037318 A CN202280037318 A CN 202280037318A CN 117377675 A CN117377675 A CN 117377675A
Authority
CN
China
Prior art keywords
compound
reaction
alkyl
added
alternatively
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CN202280037318.XA
Other languages
English (en)
Chinese (zh)
Inventor
张寅生
任景
汪纪楠
杨晓骏
张晓平
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Original Assignee
Chia Tai Tianqing Pharmaceutical Group Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Chia Tai Tianqing Pharmaceutical Group Co Ltd filed Critical Chia Tai Tianqing Pharmaceutical Group Co Ltd
Publication of CN117377675A publication Critical patent/CN117377675A/zh
Pending legal-status Critical Current

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D403/00Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D487/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Rheumatology (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Immunology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
CN202280037318.XA 2021-06-01 2022-06-01 含有并环或螺环的布鲁顿酪氨酸激酶降解剂 Pending CN117377675A (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
CN202110607649 2021-06-01
CN202110607649X 2021-06-01
PCT/CN2022/096512 WO2022253250A1 (fr) 2021-06-01 2022-06-01 Dégradation de la tyrosine kinase de bruton contenant un cycle fusionné ou un cycle spiro

Publications (1)

Publication Number Publication Date
CN117377675A true CN117377675A (zh) 2024-01-09

Family

ID=84323919

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202280037318.XA Pending CN117377675A (zh) 2021-06-01 2022-06-01 含有并环或螺环的布鲁顿酪氨酸激酶降解剂

Country Status (2)

Country Link
CN (1) CN117377675A (fr)
WO (1) WO2022253250A1 (fr)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023072270A1 (fr) * 2021-10-29 2023-05-04 百极弘烨(南通)医药科技有限公司 Composé protac, composition pharmaceutique le comprenant, son procédé de préparation et son utilisation
US20230373950A1 (en) 2022-03-17 2023-11-23 Gilead Sciences, Inc. Ikaros zinc finger family degraders and uses thereof

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP5985658B2 (ja) * 2012-01-31 2016-09-06 ナンジン アルゲン ファルマ カンパニー リミテッドNanjing Allgen Pharma Co. Ltd. ブルトンチロシンキナーゼ阻害薬としての環状分子
US8940893B2 (en) * 2013-03-15 2015-01-27 Boehringer Ingelheim International Gmbh Heteroaromatic compounds as BTK inhibitors
US9840509B2 (en) * 2014-02-03 2017-12-12 Cadila Healthcare Limited Heterocyclic compounds
EP3405192A4 (fr) * 2016-01-21 2019-07-03 Zibo Biopolar Changsheng Pharmaceutical Co. Ltd. Inhibiteurs de la tyrosine kinase de bruton
EP3426637B1 (fr) * 2016-03-11 2022-02-09 Angel Pharmaceutical Co., Ltd. Composés et procédés pour moduler la tyrosine kinase de bruton
WO2019127008A1 (fr) * 2017-12-26 2019-07-04 清华大学 Composé de dégradation ciblée de btk et son application
CN113544130B (zh) * 2019-05-31 2024-01-09 西藏海思科制药有限公司 一种btk抑制剂环衍生物及其制备方法和药学上的应用
CN112010858B (zh) * 2019-05-31 2023-07-18 四川海思科制药有限公司 一种btk抑制剂及其制备方法和药学上的应用
WO2020252397A1 (fr) * 2019-06-12 2020-12-17 Baylor College Of Medicine Chimères ciblant la protéolyse à petites molécules et leurs méthodes d'utilisation
US20220281876A1 (en) * 2019-07-26 2022-09-08 Beigene, Ltd. Degradation of bruton's tyrosine kinase (btk) by conjugation of btk inhibitors with e3 ligase ligand and methods of use
CN110845500B (zh) * 2019-10-09 2021-05-11 清华大学 靶向btk降解化合物在治疗自身免疫系统疾病中的应用
CN110724143B (zh) * 2019-10-09 2021-03-23 清华大学 一种靶向btk蛋白降解化合物的制备及其在治疗自身免疫系统疾病与肿瘤中的应用
WO2022007824A1 (fr) * 2020-07-07 2022-01-13 四川海思科制药有限公司 Composé ayant une activité de dégradation de la kinase btk, son procédé de préparation et son utilisation pharmaceutique

Also Published As

Publication number Publication date
WO2022253250A1 (fr) 2022-12-08

Similar Documents

Publication Publication Date Title
CN113651814B (zh) Kras突变蛋白抑制剂
ES2957233T3 (es) Inhibidores de quinasa tipo receptor de activina
RU2696270C1 (ru) Производные тетрагидроимидазопиридина в качестве модуляторов активности tnf
CN104520290B (zh) 酰氨基螺环酰胺和磺酰胺衍生物
CN104024255B (zh) 作为btk活性的抑制剂的烷基化哌嗪化合物
JP6165977B2 (ja) ヘテロアリールピリドン及びアザ−ピリドンアミド化合物
AU2020232026A1 (en) Carboxamide-pyrimidine derivatives as shp2 antagonists
RU2677699C1 (ru) Производные имидазотриазина в качестве модуляторов активности tnf
EP3604306A1 (fr) Dérivé macrocyclique de pyrazol[3,4-d]pyrimidin-3-one, composition pharmaceutique et utilisation associée
CN108003161B (zh) 神经营养因子酪氨酸激酶受体抑制剂
CN117377675A (zh) 含有并环或螺环的布鲁顿酪氨酸激酶降解剂
EA036630B1 (ru) Бициклические производные
RU2677698C1 (ru) Производные триазолопиридазина в качестве модуляторов активности tnf
US20230219979A1 (en) PYRAZOLO[1,5-a]PYRIDINE COMPOUND, PREPARATION METHOD THEREFOR AND USE THEREOF
CN109721600B (zh) 一类含氮稠环化合物及其制备方法和用途
JP2017508779A (ja) ROS1阻害剤としての置換4,5,6,7−テトラヒドロ−ピラゾロ[1,5−α]ピラジン誘導体および5,6,7,8−テトラヒドロ−4H−ピラゾロ[1,5−α][1,4]ジアゼピン誘導体
KR20170129192A (ko) Tnf의 억제제로서 유용한 헤테로시클릭 화합물
JP2023538091A (ja) Btk阻害剤としての複素環式化合物
US20240025907A1 (en) QUINAZOLINE PAN-KRas INHIBITORS
CN110857300B (zh) 一类稠环三氮唑类化合物、制备方法和用途
CN116496271A (zh) 含有哌嗪基的化合物
CN111253397A (zh) Mnk抑制剂
CN116761603A (zh) 含有苯并杂环的作为egfr激酶抑制剂的大环化合物、其药物组合物和用途
CN112300173B (zh) 一类含氮多环类化合物、制备方法和用途
US8492398B2 (en) Spiroazaindoles

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication